Drug Approval | July 04, 2023
Lupin receives approval from FDA for Cyanocobalamin Nasal Spray
Cyanocobalamin Nasal Spray (RLD Nascobal) had estimated annual sales of USD 69 million in the U.S. (IQVIA MAT Mar 2023)
Cyanocobalamin Nasal Spray (RLD Nascobal) had estimated annual sales of USD 69 million in the U.S. (IQVIA MAT Mar 2023)
Lupin has received US$ 25 million from AbbVie for initiation of Phase 1 clinical studies successfully
This product will be manufactured at Lupin's Pithampur facility in India
The partnership aims to prioritize the diagnosis and treatment of these diseases while working to reducing their long-term prevalence
Thiamine Hydrochloride Injection USP had estimated annual sales of USD 35 million in the U.S.
The inspection closed with the facility receiving an inspection classification of NAI
Obeticholic Acid Tablets had estimated annual sales of US$ 262 million in the U.S. (IQVIA MAT Mar 2023).
The company has reported total income of Rs. 4467.35 crores during the quarter ended March 31, 2023
The acquisition of Medisol is part of Lupin's strategy to expand its presence in the EU
Valbenazine Capsules (RLD Ingrezza) had estimated annual sales of USD 1,235 million in the U.S. (IQVIA MAT December 2022).
Subscribe To Our Newsletter & Stay Updated
